This inventor holds 3 USPTO granted patents and 5 published patent applications and 3 EPO patents. Top assignee: Mina Therapeutics Limited. Active years: 2021-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2024
Title: Jon Voutila: Innovator in saRNA Therapeutics
Introduction
Jon Voutila is an accomplished inventor based in London, GB, recognized for his significant contributions to the field of therapeutics through his innovative work with saRNA compositions. With three patents to his name, Jon has dedicated his career to developing advanced solutions that target critical biological processes.
Latest Patents
Jon Voutila's latest patents focus on saRNA targeting the HNF4a transcript. His first patent, titled "HNF4a saRNA compositions and methods of use," provides detailed therapeutic compositions that include the saRNA. This invention encompasses methods to utilize these therapeutic compositions effectively. His second notable patent, "Stabilized HNF4A saRNA compositions and methods of use," similarly targets the HNF4a transcript and outlines both the design of the saRNA as well as its therapeutic applications, signaling an innovative approach in this area of research.
Career Highlights
Jon serves as a vital member of the team at Mina Therapeutics Limited, where he leverages his expertise to push the boundaries of therapeutic development. His work is essential in exploring novel ways to enhance the efficacy of saRNA technologies, aiming to revolutionize treatment methods for various health conditions.
Collaborations
Throughout his career, Jon Voutila has collaborated with talented professionals, notably Hans E. Huber and David Blakey. These collaborations highlight the importance of teamwork in the innovation process, driving forward research and development initiatives that can lead to transformative outcomes in medicine.
Conclusion
Jon Voutila exemplifies the spirit of innovation in the field of saRNA therapeutics. With a focus on developing targeted solutions for health challenges, his contributions through patents reflect a dedication to enhancing therapeutic efficacy and patient outcomes. As he continues to work at Mina Therapeutics Limited, the future looks promising for further breakthroughs under his inventive guidance.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile